SciELO - Scientific Electronic Library Online

vol.62 número6Mortalidad en menores de cinco años mexicanos en 2004: hacia los objetivos del milenioAsociación del crecimiento físico con la composición corporal en escolares de Xochimilco índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados

  • No hay artículos similaresSimilares en SciELO


Boletín médico del Hospital Infantil de México

versión impresa ISSN 1665-1146


BARRAGAN-PEREZ, Eduardo; GARZA-PENA, Arturo; BENAVIDES-GUERRERO, Oscar  y  HERNANDEZ-AGUILAR, Juan. Risperidone in the treatment of acute disruptive behavior in pediatrics patients with epilepsy. Bol. Med. Hosp. Infant. Mex. [online]. 2005, vol.62, n.6, pp. 421-427. ISSN 1665-1146.

Introduction. Disruptive behavior (DB) is frequent in pediatric patients with epilepsy.This conducts impacts on the functioning of the children, and often leads to their social rejection. The objectives of this study were to observe the efficacy and safety of risperidone in the treatment of acute disruptive behavior in pediatric patients with epilepsy. Material and methods. A clinical open label, prospective study with a month follow up was carried out. Pediatric patients with epilepsy (partial or generalized) and disruptive behavior, both gender, between 5 and 14 years of age seen in the neurology department, Hospital Infantil de Mexico, were enrolled.The efficacy was evaluated with CGI, Peers scale and ADHD RS. Number of seizures and secondary effects was evaluated with the same methods. Results. A total of 23 patients, 7 females and 16 males enter the study with a relation M:F of 1.5:1. All the patients had epilepsy, either partial or generalized.The average doses of risperidone was 0.75 mg/kg/d, with and efficacy of 91 % at the final of the 4 weeks follow up.The more frequent side effects were increase in weight in 12 patients, extrapiramidal symptoms (head and neck discinesias) sialorrhea, thirst and somnolence. Conclusions. With these results, we support in this clinic open label study, the efficacy and safety of the use of risperidone in the management of acute disruptive behaviors in pediatric patients with epilepsy.

Palabras llave : Epilepsy; behavior; disruptive; risperidone.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License